PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States
Abstract
Authors
J. Xie Z.Y. Zhou C.N. Bui Y. Yan G. De M.C. Runken E.Q. Wu